make non-materi tweak model morn result
small chang oper expens assumpt chang ep remind
last week reduc estim eluvia consid worst
case next data point eluvia paclitaxel mid-jun eluvia suppos
biggest near term growth driver peripher busi accord
even fda remain neg paclitaxel march
letter think need chang overal compani revenu growth
guidanc upsid less like point think close worst case
discount
separ week ago host confer call ceo mike mahoney
part on-going joint ceo confer call seri today publish call
transcript note convers provid solid remind
differ growth driver across divis found clearli bullish comment
neuromod market growth outlook particularli interest light recent
manag chang
keep mind call happen march fda letter paclitaxel
reiter buy rate strong outlook across bsx busi
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
develop manufactur
market medic devic use
gynecolog neuromodul
believ grow revenu
rang go forward confid top line
on-going margin dilig also suggest
oper margin stori signific
opportun continu consist oper
leverag could drive consist double-digit
earn growth next year
particip call
mike mahoney chairman ceo
susi lisa vice-president investor relat
bob hopkin okay thank everybodi join us morn appreci
thrill today senior execut boston scientif
line know mike mahoney compani obvious ceo susi lisa
run investor relat
part sort on-going joint confer call seri
obvious one import visibl name med tech
get start want mention know disclosur pleas see
invit note went
know well get start mike susi thank know
much join us morn realli appreci
bob hopkin want cover three main topic today okay rattl
set stage know one talk bit sort durabl growth
opportun durabl know kind current
growth trend that obvious import topic investor
given hope verg lotu edg launch want
talk littl bit well
lastli want close talk med tech littl broadli
know talk mayb potenti risk given
nice long run group want get sens thing
mind potenti risk perspect long-term
well start durabl side guess way id ask sort first sort
big pictur question revenu growth guidanc guy offer
highest growth guidanc youv given long time
ask specif futur broadli speak know
view mean somewhat uniqu year given launch
happen like eluvia lotu other sort high
higher singl digit growth sustain given way youv reshap
posit compani last year
want get question durabl growth thank
mike mahoney sure ye definit latter know ive
push seven year think feel confid continu deliv
long term strateg plan
big major focu strong diversif busi know
massiv concentr db year ago consist
deliv share gain core busi consist diversifi portfolio
take share core busi consist expand high growth
youv track compani know first join let
know stop neg declin next chapter let grow market
goal grow market expect deliv top
that by-product signific diversif portfolio across
busi diversif europ asia deliv know last year
growth europ know asia-pac
excel diversif across busi
think comfort thing us weve got mani excit
product dont reli one blockbust product either drive signific upsid
signific downsid layer consist organ growth due
solid execut expans excit area know talk
team deliv strategi would say know look
know know realli top tier organ revenu growth
expect base momentum compani portfolio
bob hopkin isnt know mean kind except year
seem anyway given launch your therefor your
comp noth previou year
consid kind growth least somewhat
anomali given dynam happen launch lot realli interest
product year right way look
mike mahoney ye think expect good year year sure
know last year grew oper organ year guid know
organ guid uptick organ well
impact
think weve got nice new product line come
similar cadenc new platform thatll approv kind
anniversari oper organ mani activ
place think mani earli think theyll lot
impact know
realli dont look blip expect crater growth
bob hopkin okay right that help perspect coupl thing
come recent get product area id love get
comment
know obvious there paclitaxel sort back news neuro
growth sort back news mayb quickli start paclitaxel
realiz topic sort beaten death
know sort new inform marketplac week relat
drug-elut stent that marketplac peripheri
know cook trial data confus
mayb quickli address paclitaxel confid base
inform today know wont issu eluvia
drug-elut peripher product broadli
mike mahoney ye broadli pi pi strong know
deliv like without eluvia ill touch paclitaxel
second sale without eluvia made eluvia lot month sale weve got
strong franchis within pi ill get paclitaxel second
pi growth realli broad-bas drug-elut product
talk intervent oncolog product also mayb what
unnot growth pi asia-pac europ becom
much signific us specif asia-pac
strength pi busi broadli obvious doubl
btg quit signific beyond well also ad veniti new venou
stent portfolio first label stent well
hope close btg significantli enhanc categori leadership pi
know beyond drug-elut
first messag pi busi robust divers portfolio
respect paclitaxel know jeff mirviss said know intern
meet know proud imperi data show superior
silver lower dosag rate competit excel
clinic data
expect weve seen resist custom broadli
eluvia launch go plan properli price expect given
data approv japan well also believ
pi accret overal growth us overal growth rate
headwind data kind surpris us
know comment cook made recent
overal base physician check weve made well publish
confer taken place confid eluvia nice growth
driver us longer term nice piec overal pi busi
bob hopkin latest inform doesnt chang view outlook
eluvia drug-coat platform your bring market
mike mahoney think creat obvious lot headlin nois issu
custom
whole base data superior eluvia believ
meaning growth driver us beyond despit
bob hopkin know put headlin side quick
second know eluvia obvious there opportun displac
there much bigger opportun know displac bare metal market
that mean obvious that hundr million dollar
potenti opportun think know kind one drug-
coat stent competitor broader opportun convert bare metal
drug-coat like weve seen year ago coronari market sort opportun
sort wholesal convers
obvious well get paclitaxel nois right
broadli think opportun
mike mahoney ye think depend market know depend
reimburs certain market better other
develop market that certainli opportun
mayb emerg market know price reimburs
may strong
think that certainli opportun us gun that one
reason strategi think what realli uniqu pi
invest weve made year continu
mike mahoney comprehens portfolio know
compani lead drug-elud stent superior data ranger dcb
confid clinic data well offer uniqu benefit
comprehens well btk program combin
angiojet capabl well post-clos btg
think full portfolio whether your outpati lab
hospit abil contract across portfolio uniqu think
clear categori leadership across arteri venou intervent
product uniqu purchas contract capabl within
servic line strong us
bob hopkin okay that import help context area that
big growth driver that littl bit increment
inform marketplac late neuromod
kind increment inform sinc guy report realli
know report littl bit slower expect growth last
night provid guidanc spinal cord busi
guess question last month gave guidanc
thought neuromod market broadli think said thought
could growth market
could mayb talk know confid
know light fact spinal cord market slow littl bit weve
got other make interest comment
mike mahoney ye bullish comment
youv seen grew busi last year tougher
dont see market clearli see doubl digit growth market neuromod
year come dont see market that slow like mayb
competitor recent call
think look past two year youv seen strong doubl digit market
dont believ dynam chang there lot innov
busi wavewrit extrem well know similar
competit lost earli share initi launch europ
australia claw share back base clinic benefit longer term
weve seen wavewrit
think overal market healthi clearli doubl digit market view
continu expect take share despit tougher comp weve got
strong group strong clinic group there lot innov come
still busi
think along know structur heart ep coupl market
one stronger market med tech dont realli subscrib
mid-singl digit growth market neuromod
bob hopkin that combin confid deep brain
stimul spinal cord stimul obvious your busi
know db small grow nice super clear know
kind confid market
mike mahoney ye comment made orient spinal cord
mike mahoney think look db market tradit that
mayb upper singl digit growth market think db market move
doubl digit growth market base better technolog market there
platform competit come improv platform
there improv procedur time make effect procedur
there grow awar market
think consist upper singl digit growth market histor
think enhanc innov market awar improv product
hospit move doubl digit growth busi
mike mahoney im sorri think itll move doubl digit growth market
think know final full product approv well mri
approv come next
come low base obvious expect take share given
new us
bob hopkin right that help mean obvious could fourth quarter
inform pretti new know still look like doubl digit market even
consid player report far appreci comment
mike mahoney broadli think db doubl digit market back
db give us lot confid weve done europ
know werent player db three four year ago
weve taken signific amount share europ concentr market
term expert product excel reput expect
success
bob hopkin okay one question around sort durabl durabl
question littl bit geograph question two thing one made
comment call know japan know optimist
term growth outlook wonder could develop littl
bit
also know emerg market think lot us almost treat like
product categori know drive know two point overal
growth success
mayb talk us confid durabl growth
outlook emerg market busi sinc know drive big
percentag total growth
also wonder could flush littl bit
comment made japan call
bob hopkin sure know emerg market tough throw umbrella
theyr differ treat uniqu base
product want invest know take like latin america latin america
similar would say bsc stori overal wherea six year ago latin america
drug-elut stent market us
similar rest globe weve massiv increas invest
complex coronari portfolio your see complex non-db portfolio
larger db grow significantli
like latin america grow know much faster compani
averag enhanc non-db busi coronari diversif
portfolio endoscopi pi urolog neuromod come structur heart
watchman tavi
latin america realli diversif kind broad bsc stori
would say emerg market europ work area
like underinvest see upsid certain countri
middl east base lack underinvest would say versu peer
think that opportun us realli complex coronari
broader asia know asian countri extrem well
china fantast china kind like latin america stori
diversif beyond db across portfolio expand reach
that emerg market expect continu well base
diversif strategi wed layer
appropri market
know japan softer spot us look kind last coupl year
realli japan stori difficult reimburs market
price cut see littl less price impact
nice new product approv expect eluvia
watchman help busi japan know expect stronger
perform japan year last year especi get toward kind
second quarter beyond
japan import us given size oi back diversif
stori bsc asia use japan size china korea hong
kong taiwan busi know essenti size japan australia
grow well forth
japan get stronger us becom still import less critic
given size grow market
bob hopkin sound like lot good know good posit commentari
littl specif growth emerg market believ guy
around level think durabl know time
busi get littl bit bigger confid kind growth rate
achiev look forward
mike mahoney ye wouldnt give know guidanc specif
emerg market continu deliv expect
know kind consist emerg market growth level
tough emerg market pick right portfolio base
reimburs know landscap market
dont treat market invest harder
market lot less other combin realli latin
america busi strength china countri asia dont
expect know expect continu momentum
bob hopkin okay one thing touch china know
know mayb year two ago sort price shot across
bow coupl differ product categori
know visibl onto might come back know
visibl
mike mahoney ye us unlik lot market typic
center around db see lot know provinc call
kind consolid purchas drug-elut stent categori
potenti oral fill area
plan know call weve pretti accur
term see price eros price gain expect
continu price pressur db specif know china like everywher
get off-set complex coronari strength diversif
busi plan dont like plan price eros db
get pretti good price piec categori
realli widen commerci presenc portfolio
strength offset soft db
bob hopkin got okay broadli emerg market realiz
lot territori neg price overal
mike mahoney well dont weve made comment think whole
compani know comment know susi exactli quot
whole compani wouldnt comment emerg market think overal
mike mahoney compani know weve kind know low singl
susi lisa ye rang mike overal budget done littl
better come closer
bob hopkin okay two last question durabl ill move lotu
one get sort coupl littl product question want clarifi
someth meant ask call relat
comment made actual
street model earn growth know first
obvious there potenti ep accret that base
know that deal relat talk lot debt pay goal
know get leverag
consid thing kind seem like street model mayb
underli ep growth closer low doubl digit consid
accret debt pay
obvious your give guidanc want make sure im
miss anyth know thought process first
glanc seem high consid thing
know mayb want make sure im miss anyth
move piec think littl bit longer term
mike mahoney ye tri pretti transpar know area
know talk tax benefit earn
guid growth exclud tax benefit
think weve demonstr realli strong track record deliv doubl
digit ep target number year dont plan plan
extend streak
essenti model exclud one-tim tax benefit weve
guid basi margin improv feel comfort
also doesnt includ impact btg
realli depend btg close well expect well
provid updat guidanc post btg acquisit
commit ep accret first year close
depend close provid addit ep upsid
provid guidanc depend close
look forward think go similar playbook
know give guidanc expect deliv know organ
revenu growth know near high-end peer group expect
continu improv margin like weve said consist
excel tax rate team earn see long term
visibl plan pay debt said
confid continu deliv doubl digit ep growth
bob hopkin okay fair say think thing there extra
tailwind relat deal accret that yet guidanc know plu
know debt pay
mike mahoney clearli btg guidanc well add
close well continu deliv doubl digit ep growth
bob hopkin okay last question durabl mayb think
longer term weve talk think confid
express begin call mayb could go
mayb top three three four product product categori know
give confid sustain growth
mike mahoney ye could spend half hour topic think speak
strategi diversif go togeth know take
intervent cardiolog histor domin db
know yearend your go see complex coronari busi
equal larger db busi grow line accret bsc
categori offset db eros
add top within intervent cardiolog structur
heart perform gave guidanc number
watchman acur momentum see europ well launch
 trial later year acur launch lotu
layer top within cardiolog exampl durabl
massiv transform one busi high growth market
durabl
think obvious term dollar growth your go see quit bit
structur heart on-going strength watchman accept
protect tavi sentinel that pure cant make enough issu
work addit enhanc acur launch
think that long term durabl growth stori within cardio touch
peripher busi continu evolv launch cadenc drug-
elut product veniti addit btg know within peripher that
big one us
anoth one endo uro gem busi us look
uro busi similar look durabl busi base
innov know use stone busi kind like cardiolog use
db busi
weve disrupt market urolog single-us scope
continu enhanc platform stay ahead competit imag
chain eas use featur
weve ad earli show durabl augmenix
acquisit go well nxthera acquisit go well
less base bph longer nvision ovarian cancer detect
that excit know ep struggl us
bullish specif use cryterion balloon cryo competitor
hope launch fourth quarter europ
go rest think busi im pleas
busi grow faster except ep competitor
core busi busi kind offshoot growth new area
think quit durabl
bob hopkin sorri one last question durabl know guy laid
clearli us capac near term
kind two area kind excit adjac yet
particip im curiou priorit perspect your sort
interest expand neuro franchis area stimul
also obvious long histori stroke
know two area could see organ know strateg
know busi develop area interest
mike mahoney theyr great area make lot sens
us know number invest neuro compani
potenti could expand scope beyond spinal cord db futur
like lot whole microelectron area capabl combin
neuromod group logic us time expand
neuromod busi therapi that area look
stroke great market wish wouldnt sold year ago
that great busi challeng want focu us
categori leadership realli point effort area grow
uniqu categori leader
that bit challeng market given landscap
bob hopkin ye right let shift gear littl bit talk lotu
edg know upcom launch
guess first question id ask quickli know relat commentari made
call id love go realli quickli know
kind gave increment confid could see earli launch
know unit state
mike mahoney know stay close approv
process know feel like well like get approv know potenti
earli second quarter
want provid full year structur heart guidanc
assumpt realli reason
feel like well like get approv said earlier second quarter give
full year full structur heart guidanc know excit final launch lotu
weve got team that fulli train long time come
lot physician excit weve work mani doctor
year variou clinic studi that well point effort
know call first whatev six month term launch
product doctor use use want use
well build momentum well widen beyond clinic
site weve initi start
bob hopkin tri pars guidanc structur heart
look know assumpt move piec know kind
came estim embed guidanc know lotu sale
mayb someth million rang would
know type market share know
know dont break structur heart id love think
materi your assum know would love comment
mike mahoney ye dont pull apart think whole basket weve
provid guidanc toward know go launch lotu
go realli realli well great outcom import us build
momentum great know posit experi gate
give us physician commun confid think
youv heard number time think characterist lotu
florida week physician love complet recaptur abil
posit capabl particularli benefici heavi calcifi valv
uniqu benefit think physician combin
protect tavi strategi think physician use get comfort
expand time well follow acur launch
 get know fda approv
wont break-out lotu think look know durabl
know us ramp suppli sentinel ramp usag lotu
bring acur market obvious expans watchman
pretti strong growth driver us
bob hopkin restrict capac strain sentinel
improv get fix
mike mahoney fix grow know bought
small compani there strong demand essenti put lot
resourc creat enhanc manufactur capabl
fix take babi make put steroid that
team
think think think good chanc becom standard care
tavi im sure youd want procedur without
think go uniqu growth driver us lot intern
effort creat enough capac
bob hopkin like meet demand today
mike mahoney would say challeng physician want use
global exce current capac
mike mahoney care mani dont want disappoint
custom focu custom use dont
want spread thin issu doc use cant
use
would say right demand greater suppli work
bob hopkin opportun sentinel know import
stand-alone devic know way effect bundl
lotu way would allow grab tavr share could
sell lotu alon mean someth realli help tavr
mike mahoney think know weve seen tavi first
excel valv weve seen europ growth acur
desir acur valv expect similar thing lotu
first valv stand term perform assum
acur confid lotu protect
tavr alongsid uniqu know certainli provid differ commerci
advantag versu
bob hopkin know confid earli day major
center convers will carri three valv
mike mahoney think lotu mu valv know
accept lotu would know think margin
that excit know lotu differ lotu know
versu compet valv come market
lotu provid uniqu clinic differenti versu edward
particularli heavi calcif bicuspid area
think doctor migrat everyday valv
use
think uniqu lotu give us confid
third third market differ
know europ see know quit bit success acur
know mani account carri two three sometim four valv shelf
see day physician realli look know prescreen
make determin valv type ideal
think fact well tavr compani progress forward global
thatll super angular valv inter-angular valv combin
compani protect tavr think give hope give us confid
durabl tavi capabl
bob hopkin mayb could walk us get fda approv
know need done kind execut success launch know
mean mani doc alreadi experi know lotu
 know train know curiou kind
progress happen get approv
mike mahoney alreadi know site go go
know well get approv well well ramp much like know
watchman know devic like know well start know
physician involv clinic trial segment well
know begin launch first well continu expand
physician part clinic trial
get know beyond youll certainli widen
custom know id probabl wouldnt give detail
bob hopkin remind us mani physician involv clinic
trial like mani folk experi lotu center
mike mahoney dont susi dont know weve given number
number dont know exact number specif site part
susi lisa dont either sorri
bob hopkin mean ye that curiou mani physician
circl back
know ill anyth els want mention lotu
one thing want ask mayb updat potenti
strategi get acur what kind best case scenario
know versu like scenario
ye mayb well leav know kind updat
acur strategi what best case what like case
mike mahoney acur well next gen valv
approv europ second half contain skirt weve patent
protect itll contain well enhanc well reduc sheath
size acur well start clinic trial think second half
 earli mayb earli third quarter think roughli time
hope well fulli enrol yearend thereabout well
seek obvious fda approv
acur extrem well europ continu make enhanc
portfolio think what uniqu look know
forth posit acur super angular valv
capabl lotu differ valv acur
think think promis tavi outlook that probabl enough
tavi side think know tavi side obvious import know
watchman get littl bit lost know watchman significantli bigger
tavr product weve talk grow significantli
excit launch flex second half year europ
without go medsurg busi lot product launch
quit frankli impact lotu even year
bob hopkin mean move risk mayb know
metric side could know highlight thing think realli
critic driver outsid need pay attent
mike mahoney think probabl know know
mike mahoney realli strong divis us grow like accret
growth rate year work theyr endolumin surgeri could
look theme durabl continu pull piec togeth
portfolio think creat strong endolumin surgeri capabl bring
gener surgeon intervent gi weve got excit platform
dispos scope know multibillion dollar market hope disrupt
hope well launch end year youll get know full year
benefit
endo continu well touch urolog earlier
growth driver
bob hopkin guess know youv got analyst day
upcom year expect sort similar format last analyst day
youll give kind three year forward look know might go
littl bit mayb broad stroke perspect set expect
analyst day
mike mahoney ye like similar previou year realli detail
innov portfolio innov focu across bu
expand faster grow market portfolio serv
thatll bulk
financi well like provid view three year know high level view three
year similar weve done past touch product
beyond three year dont know interest
im sure interest
bob hopkin right analyst day mean
mike mahoney ye analyst day
bob hopkin ye mean ye would say gener peopl focus
next three year alway interest what pipelin could
meaning compani
one last topic want address realli macro question
know incred last five six year specif
realli entir medic devic space there lot innov drive quit
bit growth know expans emerg market sort bit
golden age
think alway appropri know remind potenti
risk place start know one thing know kind
think relat boston scientif med tech broadli know
potenti threat sort would character mayb
gener comment know potenti risk side equat
mike mahoney ye risk side know think clearli know price
alway top mind us assum competitor that innov
critic know disrupt creat new capabl drive know
econom benefit well clinic benefit
innov engin critic that spend know high-end
peer group weve activ tuck-in vc portfolio
price alway top mind speak diversifi
aggress area beyond know db price one think
regulatori environ alway stand toe one
know modif european mbr process year think put
pressur quickli product get approv europ that
someth know prepar your see vc compani focu
mayb potenti fda trial strategi given kind hurdl rate
higher eu clinic area
see alway chang regulatori landscap differ countri
asia well that someth stay close weve got good clinic
think mayb next near term think price reg
someth awar top think thing
discuss quit bit artifici intellig digit capabl
realli import us see tool augment solut
rather know competitor leverag capabl
partnership googl partnership enhanc digit
capabl realli led neuromod watchman franchis europ
dont see googl amazon compani near term big
competitor kind augment potenti benefit solut
bob hopkin price regulatori front anyth new go
besid mention europ price kind like think
mayb last six month anyth that come that increment risk know
rel last year
sort question regulatori front besid what go europ
mean anyth term value-bas care your watch that new mean
know sort alway risk im wonder theyr
increment risk reason
mike mahoney wouldnt call increment differ saw
plan futur think there alway plan price eros certain
segment plan flat price plan price improv gain
dont think increment neg plan
noth increment new
reg isnt realli anyth new sometim know china youll
differ clinic requir base local studi requir
forth realli stay game good capabl
bob hopkin issu like gener util know kind
surgic procedur volum anyth your see that know worth
comment obvious growth know med tech lot faster
growth surgic procedur surgic volum gener lot
innov
know anyth your see gener util front that worth
comment
mike mahoney mean realli think fortun primarili
intervent compani basic stuff think turn procedur
surgic intervent cost effect theyr hospit less
think your see continu innov intervent capabl
across board within bsc
leverag across divis think know gener
surgeri surgic compani think fortun intervent
weight base econom econom benefit intervent
bob hopkin okay close one last thing want kind ask
know tavr launch realiz there lot bigger product boston
matter
new boston import market gener
med tech know come know quit late rel
know mayb like your compet edward
strong competitor know realli thing give confid
success tavr launch rel tough
mike mahoney compet time know
know theyr good competitor know quit well id say
hold weve grow faster weve got rich pipelin
dont want repeat much think lotu valv differ
valv come copycat core valv know wouldnt
quit optimist
think physician use lotu want know uniqu
specif patient perform optim versu edward
believ custom tri extrem
strong clinic extrem strong commerci also broad
categori appropri contract purpos appropri
leverag need
bob hopkin okay think that time mean one last macro
thing know ive gotten coupl question sinc guy report
know high level question guy know made comment
know your enter new market repres sort know billion
increment opportun rel gener billion revenu today
know never realli got flush call dont time go
detail
definit thought interest comment know goe
back question durabl think import question
know investor
dont know kind broad comment billion
number threw assum relat deal youv
involv everyth your look right
there anyth particular worth call within billion id
know love hear know close
mike mahoney ye dont think want slide basic
focu investor day there slide lay show
within busi essenti adjac market capabl
product launch
essenti lay roadmap think durabl know
product platform either done organ
acquir launch know within next three year kind
cross busi
touch lot call today structur heart mention stuff pi
well think kind hit
essenti highlight beyond core busi well
adjac enter grow faster continu diversifi
busi
bob hopkin terrif that time mike susi thank
much time today appreci insight import question
thank particip
price object deriv cash ep estim
premium larg cap med-tech comp group justifi believ given view
acceler earn growth outlook base opportun drive
averag top line growth meaning oper leverag
downsid risk price object de competit dynam
increment price pressur dilut declin reimburs
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
